A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2025
This article has no abstract
Epistemonikos ID: a37df68c0022840a82d20f82b56efa2b37d50936
First added on: Apr 24, 2026